

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors in the order listed on Form Page 2. Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Merit E. Cudkowicz		POSITION TITLE Associate in Neurology at Massachusetts General Hospital Professor at Harvard Medical School	
eRA COMMONS USER NAME (credential, e.g., agency login) CUDKOWICZ			
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable.)			
INSTITUTION AND LOCATION	DEGREE (if applicable)	MM/YY	FIELD OF STUDY
Massachusetts Institute of Technology, Cambridge MA	B.S.	1985	Chemical Engineering
Harvard Medical School, Boston MA	M.D.	1990	Medicine
Harvard School of Public Health, Boston MA	M.Sc	1996	Clinical Epidemiology

D. Personal Statement

My research and clinical activities are dedicated to the study and treatment of patients with neurodegenerative disorders, in particular amyotrophic lateral sclerosis (ALS) and Huntington’s Disease (HD). My major research focus has been on developing novel treatments of these disorders. In this regard, I have performed many animal studies to evaluate a wide range of treatment strategies in ALS. Further, I have designed and initiated human clinical trials to evaluate the safety and effectiveness of therapies that have shown promise in preclinical studies. I have built the Neurology Clinical Trial Unit (NCTU) at MGH and also formed an international consortium to test novel therapies in ALS. My research efforts also include studies risk factors for the development of ALS and biomarkers. I received extensive training in clinical research methodology. I teach neurology residents and mentor neuromuscular and ALS research fellows. I currently have 2 RO1s from the National Institute of Neurological Disorders and Stroke (NINDS), a clinical research training course development grant and several others research grants to conduct clinical research and training in ALS and HD. Taken together, my research efforts constitute a comprehensive program to translate basic science breakthroughs into effective treatments for patients with ALS and those with HD.

Dr. Cudkowicz serves on the boards of scientific advisors for the Muscular Dystrophy Association and the ALS Association. She is 2009 recipient of the Sheila Essay Award for ALS research. Additionally, she is Co-Chair of the Northeast ALS Consortium (NEALS), a multi-center collaborative group formed to design and implement clinical trials in ALS and the Chair of the North American ALS Research Group. She is an active member of the American Academy of Neurology and serves as Chair of the Clinical Research Subcommittee and the Research Council. She serves as Chair of several Data Safety Monitoring Boards.

E. Positions and Honors

- 1990-1991 Intern in Medicine, Beth Israel Hospital, Boston, MA
- 1991-1994 Resident in Neurology, Massachusetts General Hospital, Boston, MA
- 1993-1994 Chief Resident in Neurology, Massachusetts General Hospital, Boston, MA
- 1994-1996 Clinical Research Fellow, Massachusetts General Hospital, Boston, MA
- 1995-1997 Instructor, Department of Neurology, Harvard Medical School, Boston, MA
- 1996-2002 Assistant in Neurology, Massachusetts General Hospital, Boston, MA
- 1997-2002 Assistant Professor, Department of Neurology, Harvard Medical School, Boston, MA
- 2002- Associate Professor, Department of Neurology, Harvard Medical School, Boston, MA
- 2002- Associate in Neurology, Massachusetts General Hospital, Boston, MA
- 1996- Co-Chair, NorthEast ALS Consortium
- 1997- Co-Director Neurology Clinical Trial Unit, Massachusetts General Hospital, Boston, MA
- 1997- 2008 Co-Director, ALS Center, Massachusetts General Hospital, Boston, MA

2008 Director, ALS Center, Massachusetts General Hospital, Boston, MA
2007-2009 Vice Chair, ALS Research Group
2009- Chair, ALS Research Group
Honors
1985 Tau Beta Pi Engineering Honor Roll, M.I.T.
1989 Massachusetts Medical Society student research award
1998 Will Solimene Award in Excellence in Medical Communication
2003 Angel Fund Award in ALS Research
2006 Wings Over Wall Street MDA ALS Research Award
2009 Sheila Essey AAN ALS Research Award

F. Selected Peer-reviewed Publications (Selected from 104)

1. Ferrante K, Shefner J, Zhang H, Betensky R, Brien M, Yu H, Fantasia, M Taft J, Beal MF, Traynor B, Newhall K, Donofrio P, Caress J, Ashburn C, Freiberg B, O'Neill C, Paladenech C, Walker T, ; Pestronk A, Abrams B, Florence J, Renna R, Schierbecker J, Malkus B, **Cudkowicz M**. Coenzyme Q10 up to 3000 mg per day is well tolerated in amyotrophic lateral sclerosis. *Neurology* 2005;65 :1834-1836
2. Qureshi M, Hayden D, Urbinelli L, Ferrante K, Newhall K, Myers D, Hilgenberg S, Smart R, Brown R, **Cudkowicz M**. Analysis of factors that modify susceptibility and rate of progression in amyotrophic lateral sclerosis (ALS). *Amyotrophic Lateral Sclerosis and other motor neuron disorders*. 2006;7(3): 173-182
3. Traynor B, Bruijn L, Conwit RA, Beal F, O'Neill G, Fagan S **Cudkowicz ME**. Neuroprotective agents for clinical trials in ALS: Asystematic assessment. *Neurology* 2006;67:20-27
4. **Cudkowicz ME**, Shefner JM, Schoenfeld DA et al. Trial of Celecoxib in Amyotrophic Lateral Sclerosis. *Annals of Neurology* 2006;60:22-31
5. Shefner JM, **Cudkowicz ME**, Zhang H, Schoenfeld D, Jillapalli D, and the Northeast ALS Consortium. Revised statistical MUNE in the Celecoxib/ALS Trial. *Muscle and Nerve* 2007; 35(2):228-34.
6. Caraganis A, Benn S, **Cudkowicz ME**, Brown RH. Thrombopoietin is ineffective in a mouse model of motor neuron disease. *Amyotroph Lateral Scler* 2008;9(6):354-8.
7. **Cudkowicz ME**, Shefner JM, Simpson E, Grasso D, Yu H, Zhang H, Shui A, Schoenfeld D, Brown RH, Wieland S, Barber JR and the Northeast ALS Consortium. Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in ALS. *Muscle and Nerve* 2008;38 (1):837-44.
8. Qureshi M, Shui A, DiBernardo AB, Brown RH, Schoenfeld DA, **Cudkowicz ME**. Medications and laboratory parameters as prognostic factors in amyotrophic lateral sclerosis. *Amyotroph Lateral Scler* 2008; 9(6):369-374.
9. Bedlack RS, Pastula D, Welch E, Pulley D, **Cudkowicz ME**. Scrutinizing Enrollment in ALS Clinical Trials. *Amyotroph Lateral Scler* 2008;9(5):257-65
10. **Cudkowicz ME**, Andres PL, Macdonald SA, Bedlack RS, Choudry R, Brown RH Jr, Zhang H, Schoenfeld DA, Shefner J, Matson S, Matson WR, Ferrante FJ. Phase 2 study of sodium phenylbutyrate in ALS. *Amyotroph Lateral Scler* 2008;7:1-8.
11. Qureshi M, Brown RH, Rogers JT, **Cudkowicz ME**. Ferritin levels and metals as risk factors in amyotrophic lateral sclerosis. *Open Neurology Journal* 2008; 2:51-54.
12. Qureshi M, Schoenfeld D, Paliwal Y, Shui A, **Cudkowicz ME**. The natural history of ALS is changing; improved survival. *Amyotroph Lateral Scler* 2009;10(5-6):324-331.
13. Castrillo C, Grasso D, Simpson E, Shefner J, Cudkowicz ME. Clinical significance of change in ALSFRS-R. *Amyotroph Lateral Scler* 2009: In Press.
14. Gordon PH, Corcia P, Lacomblez L, Pochigaeva K, Abitbol J-P, **Cudkowicz M**, Nigel PN, Meininger V. Defining Survival as an Outcome Measure in ALS. *Archives of Neurology* 2009::66(6):758-761.
15. Qureshi M, Bedlack RS, **Cudkowicz ME**. Lyme disease serology in amyotrophic lateral sclerosis. *Muscle and Nerve* 2009: In Press